Ovarian Cancer: Effective Immunotherapy Moves Closer with a New T-Cell Study

According to United States statistics, among every 75 women, approximately 1 will develop ovarian cancer during her lifetime. In our country, ovarian cancer is the 7th most common cancer in women. About half of women diagnosed are aged 63 or older. Because it rarely causes signs in its early stages, it is usually diagnosed at stages 3 and 4 and has a greater tendency to recur after treatment. Surgery and chemotherapy are the mainstays of treatment. In recent years, PARP inhibitors , biological drugs affecting DNA repair mechanisms, have also entered the treatment landscape. However, information on whether immunotherapies, groundbreaking treatments in cancer, are effective in ovarian cancer remains limited.
Immunotherapy is a relatively new field of medicine with promising results in cancer treatment. Its basic principle is to use the patient’s own immune system to fight disease. Immunotherapy applications in ovarian cancer treatment were among the notable topics at this year’s American Association for Cancer Research (AARC) meeting. However, immunotherapy is not a single type of treatment.

A Promising Type of Immunotherapy for Ovarian Cancer: Adoptive T-Cell Transfers
We divide cancers into two groups: “solid” and “non-solid.” Solid tumors refer to cancers of specific organs such as the lung, breast, colon and prostate. Non-solid cancers belong to hemato-oncology and refer to cancers of the blood and lymphatic organs, such as leukemia and lymphoma.
A new study suggests that a method called adoptive T-cell transfer may be effective in treating ovarian cancer, a solid tumor. Cellular immunotherapy includes adoptive T-cell therapy, in which defensive cells called T cells are taken from the patient’s own blood and modified to target cancer cells. After expansion in the laboratory, these processed cells are returned to the patient’s body in an attempt to destroy cancer cells.

The research team reported success using adoptive T-cell transfer to treat leukemia, a non-solid cancer. Experience gained from this work has also led to progress in applying the treatment to solid tumors.
Can our immune cells be reprogrammed to target specific proteins released by tumors?
Ovarian cancer cells were found to overproduce two proteins — WT1 and mesothelin . Researchers discovered that T cells designed to target these proteins could kill mouse and human ovarian cancer cells in the laboratory . However, more research is needed before adoptive T-cell transfer is ready for human clinical trials .
Nevertheless, applying T-cell therapy to solid tumors such as breast, ovarian, lung and pancreatic cancer is more difficult than treating blood cancers.
In leukemia and lymphoma, processed T cells are delivered directly into the bloodstream to target cancerous cells. Reaching solid tumors within organs is not so easy and involves various challenges. One of the most important barriers to delivering therapeutic agents to solid tumors is the tumor microenvironment , the tissue surrounding a tumor containing dozens of different cell types and complex interactions.
A Previously Overlooked Factor in Cancer Treatment: The Tumor Microenvironment
The tumor microenvironment makes adoptive T-cell therapies for solid tumors more difficult in 3 ways:
- The microenvironment contains cells and protein structures in the tissue surrounding the tumor that signal T cells to become inactive or ignore the tumor. Immunotherapy drugs already in use, called “immune checkpoint inhibitors,” may help solve this problem. Another approach is producing T cells through genetic techniques that block these signals.
- Ovarian cancer cells or blood vessels surrounding the tumor were found to send signals causing T cells to destroy themselves before attacking cancer cells. Special therapeutic proteins are therefore being developed to prevent T cells from becoming inactive when they receive this signal.
- Sugar levels in the tumor microenvironment are very low because cancer cells need large amounts of sugar to multiply uncontrollably. T cells also need sugar as an energy source to multiply and attack cancer. This creates a problem when developing treatments that cut off cancer’s energy supply. To address this, researchers are testing genetically modified T cells that use a different energy source instead of sugar.
In conclusion, adoptive T-cell therapies aim to develop informed fighter cells against cancer. However, the T cells developed carry a risk of attacking our own cells. Using the genetic engineering technique CRISPR , the aim is to make T cells more specific / targeted so they attack only cancer cells. This method, particularly promising in non-solid tumors—blood cancers and lymphomas—will also offer an effective treatment for solid tumors once problems in the tumor microenvironment are resolved.
Sources
Engineering adoptive T cell therapy for efficacy in ovarian cancer.
AACR Annual Meeting 2017. Session MS.IM02.01 - Adoptive Cellular Therapy for Cancer
4980
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.